Navigation Links
PDL BioPharma to Announce Second Quarter 2009 Financial Results and Hold Conference Call July 30, 2009
Date:7/22/2009

INCLINE VILLAGE, Nev., July 22 /PRNewswire-FirstCall/ -- PDL BioPharma, Inc. (PDL) (Nasdaq: PDLI) today announced that the company will hold a conference call and webcast on Thursday, July 30 at 4:30 p.m. Eastern Time to discuss its financial results for the second quarter of 2009 and provide a business update. The call and webcast will follow the release of the second quarter ended June 30, 2009 financial results after market close.

Conference Call Details

To access the live conference call via phone, please dial (866) 510-0707 from the United States and Canada or (617) 597-5376 internationally. The conference ID is 27369299. Please dial in approximately ten minutes prior to the start of the call. A telephone replay will be available beginning approximately one hour after the call through August 6, and may be accessed by dialing (888) 286-8010 from the United States and Canada or (617) 801-6888 internationally. The replay passcode is 58547023.

To access the live and subsequently archived webcast of the conference call, go to the company's Web site athttp://www.pdl.com and click "Investors." Please connect to the web site at least 15 minutes prior to the call to allow for any software download that may be necessary.

About PDL BioPharma, Inc.

PDL BioPharma pioneered the humanization of monoclonal antibodies and, by doing so, enabled the discovery of a new generation of targeted treatments for cancer and immunologic diseases. PDL is focused on maximizing the value of its antibody humanization patents and related assets. The company receives royalties on sales of a number of humanized antibody products marketed today and also may receive royalty payments on additional humanized antibody products launched before patent expiry in late 2014. For more information, please visit www.pdl.com.

NOTE: PDL BioPharma and the PDL BioPharma logo are considered trademarks of PDL BioPharma, Inc.


'/>"/>
SOURCE PDL BioPharma, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. DOR BioPharma Appoints Christopher P. Schnittker, CPA, as Vice President of Administration and Controller
2. AlphaRx and Gaia BioPharma Report Positive Efficacy Results in a Pre-Clinical Trial of GAI-122 Injectable Nano-emulsion for Post-operative Delirium
3. Helix Biopharma Corp. Begins Trading on the OTCQX International Market Listing as HXBPF
4. Sinobiopharma Receives Trademark Approval and Authentication From Chinese Government For Its Tai Drug Series
5. Keryx Biopharmaceuticals Inc. Regains Compliance With NASDAQ Listing Requirements
6. AlphaRx and Gaia BioPharma Provide GAI-122 Development Update
7. PDL BioPharma Announces Record Date for October 1 Dividend Payment
8. Keryx Biopharmaceuticals, Inc. Receives Extension for Nasdaq Listing Compliance
9. SAFE-BioPharma Webinar Featuring ARX's Digital Signatures Combined with Microsoft SharePoint for Bio-Pharma industry
10. Prix Galien USA Now Accepting Nominations for Premiere Biopharmaceutical Industry Award
11. The Sage Group Widens Strategic Role to Assist HemispherX Biopharma in Pandemic Influenza Initiatives as Pacific Rim/Japan Treatment/Prevention Programs Accelerate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/21/2017)... West Palm Beach, FL (PRWEB) , ... April 21, 2017 , ... The staff at ... FACS , will be taking part in the 2017 London Marathon. Set to take place ... variety of charitable organizations. This year, Dr. Schwartz will run as part of team EMPOWER, ...
(Date:4/21/2017)... , ... April 21, 2017 , ... Brady ... that its B-595 and B-7569 vinyl label materials received certification ... warning labels are tested to remain intact and legible, for use on chemical drums ...
(Date:4/21/2017)... , ... April 21, 2017 , ... The Patient Advocacy ... Health System, with the 2017 Ruth Ravich Patient Advocacy Award in recognition ... advocates. DeVaro was honored with the award at The Beryl Institute’s annual Patient ...
(Date:4/21/2017)... ... April 21, 2017 , ... ... campaign, AWARE: A Week of Addiction and Recovery Education, from April 24 to ... and preventing substance use disorders. , The mission of AWARE is to ...
(Date:4/21/2017)... ... 21, 2017 , ... Metrasens is honoured to have won ... most prestigious award for business success. The company has been recognized for ... grown by a total of 400% over the last six years. , Metrasens ...
Breaking Medicine News(10 mins):
(Date:4/19/2017)... DIEGO , April 19, 2017  Sorrento ... an antibody-centric, clinical-stage biopharmaceutical company developing new treatments ... announced the closing of its previously announced underwritten ... stock at a public offering price of $2.00 ... and estimated offering expenses payable by Sorrento.  The ...
(Date:4/19/2017)... HANOVER, N.J. , April 19, 2017 /PRNewswire/ ... conducted by the National Heart, Lung, and Blood ... (NIH) demonstrating that 58% of patients with treatment-naïve ... six months when treated with eltrombopag at the ... 1 . The study evaluated three sequential treatment ...
(Date:4/18/2017)... Cogentix Medical, Inc. (NASDAQ: CGNT), a global medical device ... markets with innovative and proprietary products, will release financial ... after the market close on Tuesday, May 2, 2017. ... call and webcast to discuss its financial results the ... p.m. Eastern Time (3:30 p.m. Central Time). Darin ...
Breaking Medicine Technology: